EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes

Cindy Y Kok, Shinya Tsurusaki, Marti Cabanes-Creus, Sindhu Igoor, Renuka Rao, Rhys Skelton, Sophia H Y Liao, Samantha L Ginn, Maddison Knight, Suzanne Scott, Mario Mietzsch, Rebecca Fitzsimmons und 9 weitere

Molecular Therapy - Methods & Clinical Development · 2023-09 · 30 · 459-473

DOI: 10.1016/j.omtm.2023.08.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2023-09. Verfasst von Cindy Y Kok und 20 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Heart Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recombinant adeno-associated viruses (rAAVs) have emerged as one of the most promising gene therapy vectors that have been successfully used in pre-clinical models of heart disease. However, this has not translated well to humans due to species differences in rAAV transduction efficiency. As a result, the search for human cardiotropic capsids is a major contemporary challenge. We used a capsid-shuffled rAAV library to perform directed evolution in human iPSC-derived cardiomyocytes (hiPSC-CMs). Five candidates emerged, with four presenting high sequence identity to AAV6, while a fifth divergent variant was related to AAV3b. Functional analysis of the variants was performed in vitro using hiPSC-CMs, cardiac organoids, human cardiac slices, non-human primate and porcine cardiac slices, as well as mouse heart and liver in vivo. We showed that cell entry was not the best predictor of transgene expression efficiency. The novel variant rAAV.KK04 was the best-performing vector in human-based screening platforms, exceeding the benchmark rAAV6. None of the novel capsids demonstrate a significant transduction of liver in vivo. The range of experimental models used revealed the value of testing for tropism differences under the conditions of human specificity, bona fide, myocardium and cell type of interest.

Schlagwörter

Stichwörter der Autor:innen

adeno-associated viruscardiac organoidscardiac slicescardiotropichiPSC-CM

Autor:innen und Institutionen

  • Centre for Heart Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia.
  • Westmead Clinical School, the Faculty of Medicine and Health, The University of Sydney, Westmead, NSW 2145, Australia.
  • Translational Vectorology Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW 2145, Australia.
  • Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and Sydney Children's Hospital Network, Westmead, NSW 2145, Australia.
  • Department of Biochemistry and Molecular Biology, College of Medicine, Center for Structural Biology, McKnight Brain Institute, University of Florida, Gainesville, FL 32610-0245, USA.
  • QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4006, Australia.

Förderung

  • NHLBI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Kok, C. Y., Tsurusaki, S., Cabanes-Creus, M., Igoor, S., Rao, R., Skelton, R., Liao, S. H. Y., Ginn, S. L., Knight, M., Scott, S., Mietzsch, M., Fitzsimmons, R., Miller, J., Mohamed, T. M. A., McKenna, R., Chong, J. J. H., Hill, A. P., Hudson, J. E., Alexander, I. E., …, & Kizana, E. (2023). Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes. Molecular Therapy - Methods & Clinical Development, 30, 459-473. https://doi.org/10.1016/j.omtm.2023.08.010

Vancouver

Kok CY, Tsurusaki S, Cabanes-Creus M, Igoor S, Rao R, Skelton R, et al. Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes. Molecular Therapy - Methods & Clinical Development. 2023;30:459-473. doi:10.1016/j.omtm.2023.08.010

BibTeX
@article{Kok2023,
  author = {Kok, Cindy Y and Tsurusaki, Shinya and Cabanes-Creus, Marti and Igoor, Sindhu and Rao, Renuka and Skelton, Rhys and Liao, Sophia H Y and Ginn, Samantha L and Knight, Maddison and Scott, Suzanne and Mietzsch, Mario and Fitzsimmons, Rebecca and Miller, Jessica and Mohamed, Tamer M A and McKenna, Robert and Chong, James J H and Hill, Adam P and Hudson, James E and Alexander, Ian E and Lisowski, Leszek and Kizana, Eddy},
  title = {Development of new adeno-associated virus capsid variants for targeted gene delivery to human cardiomyocytes},
  journal = {Molecular Therapy - Methods & Clinical Development},
  year = {2023},
  volume = {30},
  pages = {459--473},
  doi = {10.1016/j.omtm.2023.08.010}
}
Kostenlos starten →